Literature DB >> 22930267

Size-dependent heterogeneity of contractile Ca2+ sensitization in rat arterial smooth muscle.

Toshio Kitazawa1, Kazuyo Kitazawa.   

Abstract

Each segment along arterial vessels adapts to different circumstances, including blood pressure and sympathetic innervation. PKC and Rho-associated kinase (ROCK) Ca(2+)-sensitizing pathways leading to myosin phosphatase inhibition are critically involved in α(1)-adrenoceptor-mediated vascular smooth muscle contraction in distinctive time-dependent manners. We tested whether the amplitude and time course of each pathway varies dynamically between arterial segments. Using pharmacological approaches, we determined the time-dependent roles of Ca(2+) release, Ca(2+) influx, PKC and ROCK in α(1)-agonist-induced contraction and phosphorylation of key proteins in denuded rat small mesenteric artery, midsized caudal artery and thoracic aorta. SR Ca(2+) release and voltage-dependent Ca(2+) influx were essential for the initial rising and late sustained phases, respectively, of phenylephrine-induced contraction, regardless of arterial size. In small mesenteric arteries, α(1A)-subtype-specific antagonists and inhibitors of PKC, but not ROCK, markedly reduced the initial and late phases of contraction in a non-additive manner and suppressed phosphorylation of myosin light chain (MLC) and CPI-17, but not myosin targeting subunit of myosin light chain phosphatase (MYPT1). In aorta, an α(1D)-specific antagonist reduced both the initial and late phases of contraction with a significant decrease in MLC but not CPI-17 or MYPT1 phosphorylation. ROCK inhibitors, but not PKC inhibitors, suppressed the sustained phase of contraction with a decrease in MLC and MYPT1 phosphorylation in the aorta. The effect of ROCK inhibitors was additive with the α(1D)-antagonist. The results for midsized arteries were intermediate. Thus, the PKC-CPI-17 Ca(2+)-sensitizing pathway, which is dependent on PKC subtype and a Ca(2+)-handling mechanism, and is downstream of α(1A) receptors, plays a major role in α(1)-agonist-induced contraction of small resistance arteries in the splanchnic vascular beds. The effect of PKC and ROCK increases and decreases, respectively, with decreasing arterial size.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22930267      PMCID: PMC3515827          DOI: 10.1113/jphysiol.2012.241315

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  64 in total

1.  Role of calcium-activated chloride current in regulating pulmonary vasomotor tone.

Authors:  X J Yuan
Journal:  Am J Physiol       Date:  1997-05

2.  Changes in cytosolic calcium level in vascular smooth muscle strip measured simultaneously with contraction using fluorescent calcium indicator fura 2.

Authors:  K Sato; H Ozaki; H Karaki
Journal:  J Pharmacol Exp Ther       Date:  1988-07       Impact factor: 4.030

3.  Perfusion cuvette for the simultaneous measurement of mechanical, optical and energetic parameters of skinned muscle fibres.

Authors:  K Güth; R Wojciechowski
Journal:  Pflugers Arch       Date:  1986-11       Impact factor: 3.657

4.  Effects of the modification of transfer buffer composition and the renaturation of proteins in gels on the recognition of proteins on Western blots by monoclonal antibodies.

Authors:  S D Dunn
Journal:  Anal Biochem       Date:  1986-08-15       Impact factor: 3.365

5.  Subtype specific regulation of human vascular alpha(1)-adrenergic receptors by vessel bed and age.

Authors:  X L Rudner; D E Berkowitz; J V Booth; B L Funk; K L Cozart; E B D'Amico; H El-Moalem; S O Page; C D Richardson; B Winters; L Marucci; D A Schwinn
Journal:  Circulation       Date:  1999-12-07       Impact factor: 29.690

6.  Role of sarcoplasmic reticulum in arterial contraction: comparison of ryanodines's effect in a conduit and a muscular artery.

Authors:  T Ashida; J Schaeffer; W F Goldman; J B Wade; M P Blaustein
Journal:  Circ Res       Date:  1988-04       Impact factor: 17.367

7.  Calcium antagonistic properties of nicardipine, a dihydropyridine derivative assessed in isolated cerebral arteries and cardiac muscle.

Authors:  K Nakayama; J Kurihara; Y Miyajima; K Ishii; H Kato
Journal:  Arzneimittelforschung       Date:  1985

8.  Real-time evaluation of myosin light chain kinase activation in smooth muscle tissues from a transgenic calmodulin-biosensor mouse.

Authors:  Eiji Isotani; Gang Zhi; Kim S Lau; Jian Huang; Yusuke Mizuno; Anthony Persechini; Ramaz Geguchadze; Kristine E Kamm; James T Stull
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-07       Impact factor: 11.205

Review 9.  Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase.

Authors:  Andrew P Somlyo; Avril V Somlyo
Journal:  Physiol Rev       Date:  2003-10       Impact factor: 37.312

10.  Acute desensitization to angiotensin II: evidence for a requirement of agonist-induced diacylglycerol production during tonic contraction of rat aorta.

Authors:  N R Danthuluri; R C Deth
Journal:  Eur J Pharmacol       Date:  1986-07-15       Impact factor: 4.432

View more
  27 in total

Review 1.  A role for the Ca(2+)-dependent tyrosine kinase Pyk2 in tonic depolarization-induced vascular smooth muscle contraction.

Authors:  Ryan D Mills; Mitsuo Mita; Michael P Walsh
Journal:  J Muscle Res Cell Motil       Date:  2015-07-07       Impact factor: 2.698

2.  Prolonged bed rest impairs rapid CPI-17 phosphorylation and contraction in rat mesenteric resistance arteries to cause orthostatic hypotension.

Authors:  Toshio Kitazawa; Kazuyo Kitazawa
Journal:  Pflugers Arch       Date:  2017-07-17       Impact factor: 3.657

3.  Myosin phosphatase target subunit 1 (MYPT1) regulates the contraction and relaxation of vascular smooth muscle and maintains blood pressure.

Authors:  Yan-Ning Qiao; Wei-Qi He; Cai-Ping Chen; Cheng-Hai Zhang; Wei Zhao; Pei Wang; Lin Zhang; Yan-Ze Wu; Xiao Yang; Ya-Jing Peng; Ji-Min Gao; Kristine E Kamm; James T Stull; Min-Sheng Zhu
Journal:  J Biol Chem       Date:  2014-06-20       Impact factor: 5.157

Review 4.  Myosin phosphatase isoforms as determinants of smooth muscle contractile function and calcium sensitivity of force production.

Authors:  Rachael P Dippold; Steven A Fisher
Journal:  Microcirculation       Date:  2014-04       Impact factor: 2.628

5.  Emodin inhibits tonic tension through suppressing PKCδ-mediated inhibition of myosin phosphatase in rat isolated thoracic aorta.

Authors:  Kyung-Min Lim; Jae-Hyuk Kwon; Keunyoung Kim; Ji-Yoon Noh; Seojin Kang; Jung-Min Park; Moo-Yeol Lee; Ok-Nam Bae; Jin-Ho Chung
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

6.  A bioinformatic and computational study of myosin phosphatase subunit diversity.

Authors:  Rachael P Dippold; Steven A Fisher
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-06-04       Impact factor: 3.619

7.  Propofol induces excessive vasodilation of aortic rings by inhibiting protein kinase Cβ2 and θ in spontaneously hypertensive rats.

Authors:  Yan Wang; Quanhong Zhou; Bin Wu; Huixuan Zhou; Xiaoli Zhang; Wei Jiang; Li Wang; Aizhong Wang
Journal:  Br J Pharmacol       Date:  2017-05-10       Impact factor: 8.739

8.  Neural programming of mesenteric and renal arteries.

Authors:  John J Reho; Xiaoxu Zheng; James E Benjamin; Steven A Fisher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-08-15       Impact factor: 4.733

9.  Nuclear localization of CPI-17, a protein phosphatase-1 inhibitor protein, affects histone H3 phosphorylation and corresponds to proliferation of cancer and smooth muscle cells.

Authors:  Masumi Eto; Jason A Kirkbride; Rishika Chugh; Nana Kofi Karikari; Jee In Kim
Journal:  Biochem Biophys Res Commun       Date:  2013-03-26       Impact factor: 3.575

10.  Smooth muscle-selective CPI-17 expression increases vascular smooth muscle contraction and blood pressure.

Authors:  Wen Su; Zhongwen Xie; Shu Liu; Lindsay E Calderon; Zhenheng Guo; Ming C Gong
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-04-19       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.